Shopping Cart
- Remove All
- Your shopping cart is currently empty
Talquetamab (JNJ-64407564) is a GPRC5D bispecific antibody for multiple myeloma (MM) that induces T-cell-mediated killing of GPRC5-expressing MM cells through T-cell recruitment and activation, demonstrating antitumor activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $289 | In Stock | |
2 mg | $437 | In Stock | |
5 mg | $723 | In Stock | |
10 mg | $1,160 | In Stock | |
25 mg | $1,720 | In Stock | |
50 mg | $2,320 | In Stock | |
100 mg | $3,130 | In Stock |
Description | Talquetamab (JNJ-64407564) is a GPRC5D bispecific antibody for multiple myeloma (MM) that induces T-cell-mediated killing of GPRC5-expressing MM cells through T-cell recruitment and activation, demonstrating antitumor activity. |
In vitro | Talquetamab, at concentrations ranging from 0.00128 to 4.0 μg/mL for 48 hours, effectively induces lysis of multiple myeloma cells. This induction is accompanied by a significant dose-dependent increase in the proportion of activated CD4+ and CD8+ T cells, as well as elevated levels of granule enzyme B and inflammatory cytokines such as IL-6, IL-8, and TNF-α [2]. |
In vivo | Talquetamab (JNJ-64407564), administered subcutaneously or intravenously at doses ranging from 0.1 to 50 µg, exhibits significant anti-tumor activity in H929 and MM mouse models [1]. |
Alias | JNJ-7564, JNJ-64407564 |
Molecular Weight | 144.59 kDa |
Cas No. | 2226212-40-2 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.